GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis

Publication date: Available online 25 April 2019Source: Reproductive BioMedicine OnlineAuthor(s): Yi Han, Yingjie Li, Bing HeAbstractThis meta-analysis aimed to evaluate the efficacy and safety of glucagon-like peptide 1 (GLP-1) receptor agonists for women with polycystic ovary syndrome (PCOS) by comparing their effect with that of metformin. Electronic databases (PubMed, EMBASE, Cochrane Library, WanFang Database, CNKI) dating from their establishment to June 2018 were searched to find all randomized controlled trials (RCTs) reporting the efficacy of GLP-1 receptor agonists versus metformin for patients with PCOS. Therapeutic variables included menstrual cycle, sex hormone and clinical manifestations, glucose metabolism and other metabolic indexes. Eight RCTs among 462 related articles were included in the meta-analysis. Compared with metformin, GLP-1 receptor agonists were more effective in improving insulin sensitivity (standard mean difference [SMD] –0.40, 95% confidence interval [CI] –0.74 to –0.06, P = 0.02) and reducing body mass index (SMD –1.02, 95% CI –1.85 to –0.19, P = 0.02) and abdominal girth (SMD –0.45, 95% CI –0.89 to –0.00, P = 0.05). GLP-1 receptor agonists were associated with a higher incidence of nausea and headache than metformin, but there were no significant differences in other data. Therefore, compared with metformin, GLP-1 receptor agonists might be a good choice for obese patients with PCOS, especially those with insul...
Source: Reproductive BioMedicine Online - Category: Reproduction Medicine Source Type: research